Figure 1




Figure 2





Figure 3



Reasons for Discontinuation	Study 1		Study 2	
	Ivermectin 1% N= 451	Vehicle N= 232	Ivermectin 1% N= 459	Vehicle N= 229
Pregnancy	2 (0.4%)	0	1 (0.2%)	0
Lack of Efficacy	0	1 (0.4%)	1 (0.2%)	0
Adverse Event	7 (1.6%)	4 (1.7%)	6 (1.3%)	4 (1.7%)
Subject Request	18 (4.0%)	7 (3.0%)	9 (2.0%)	8 (3.5%)
Protocol Violation	2 (0.4%)	1 (0.4%)	4 (0.9%)	0
Lost to Follow-up	7 (1.6%)	8 (3.4%)	8 (1.7%)	8 (3.5%)
Other	1 (0.2%)	1 (0.4%)	1 (0.2%)	1 (0.4%)

Figure 4A

** p<.001




Figure 4B




Figure 4C



SCOLANTPA
Vehicle
50%
40%
30%
20%
10%
0%
Success Rate (%)
BASE
Wk2
Wk4
Wk8
Wk12
Analysis Visit

Figure 5A




Figure 5B




Figure 5C

* p<.01, ** p<.001




Figure 5D

* p<.01, ** p<.001




Figure 6A




Figure 6B





Figure 7



IGA= 4; IL= 63



IGA= 1; IL= 2

Figure 8




Figure 9

* $p<.05$, ** $p<.001$




Figure 10

* $p<.05$, ** $p<.001$




Figure 11




Figure 12



100
90
80
70
60
50
40
30
20
10
0
% of subjects remaining without Relapse
0
14
28
42
56
70
84
98
112
126
140
154
168
182
196
210
224
238
252
266
280
294
Time from baseline (day)
Treatments:
*** CD5024 1%
*** Metronidazole

Figure 13

